Patient samples and controls

MN Mojgan Naghitorabi
JM Javad Mohammadi-Asl
HS Hamid Mir Mohammad Sadeghi
MR Mohammad Rabbani
AJ Abbas Jafarian-Dehkordi
SJ Shaghayegh Haghjooy Javanmard
ask Ask a question
Favorite

A total of 98 FFPE tissue samples from breast cancer patients, related to years 2005 to 2009, were collected from the Department of Pathology at the Imam Khomeini and Shafa University Hospitals, in Ahvaz, Iran. The samples were identified as ductal carcinoma in situ (DCIS) (n = 8), invasive ductal carcinoma (IDC) (n = 65), invasive and in situ ductal carcinoma (DCIS + IDC) (n = 20), invasive lobular and ductal carcinoma (ILC + IDC) (n = 2), and inflammatory carcinoma (n = 3). In addition, 10 fresh frozen normal breast tissue samples from the marginal tissues of tumor in breast cancer patients were obtained and analyzed. Ethical guidelines were met for sample collection.

EpiTect Methylated and Bisulfite converted Control DNA (Qiagen, Germany) and EpiTect Unmethylated and Bisulfite converted Control DNA (Qiagen, Germany) were used as positive (100% methylated) and negative (0% methylated) controls, respectively. Also EpiTect Unmethylated and Unconverted Control DNA (Qiagen, Germany) were used as the control for bisulfite modification.

A series of standard dilutions of methylated DNA was prepared by diluting 100% methylated and bisulfate-treated control DNA on a background of unmethylated and bisulfate-treated control DNA in ratios of 75, 50, 25, and 10%.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A